Dec 21 (Reuters) - Older adults taking Bayer AG's (BAYGn.DE), opens new tab blockbuster blood thinner pill Xarelto for a common type of irregular heart rhythm had significantly higher rates of serious ...

The FDA has approved Xarelto (rivaroxaban; Janssen) for the prophylaxis of venous thromboembolism (VTE) and VTE-related death during hospitalization and post hospital discharge in adult patients ...

The GALILEO trial has been halted after an early peek at the data showed that rivaroxaban (Xarelto; Bayer/Janssen) was associated with greater risks of all-cause mortality, thromboembolic events, and ...

NEW ORLEANS (AP) — The pharmaceutical companies behind the widely advertised blood thinner Xarelto reached a $775 million settlement in 25,000 lawsuits alleging patients were not adequately warned ...

Johnson & Johnson’s novel oral anticoagulant Xarelto, the current market leader in the category, may not hold pole position these among blood thinners for much longer, according to new prescription ...

Janssen announced that the Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction (MI) ...

(Reuters) - Bayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits alleging that their blockbuster blood thinner Xarelto caused unstoppable and in some cases fatal ...

In patients with active cancer who have been hospitalized for a venous thromboembolism (VTE) event, rivaroxaban (Xarelto; Bayer/Janssen) is as effective as apixaban (Eliquis; Bristol-Myers Squibb) in ...

Johnson & Johnson's pharma unit is still churning out growth, partly because of outperforming new launches like cancer med Darzalex. But execs had to explain away some disappointing results for two of ...

Medicare Part D and Medicare Advantage plans with prescription drug coverage may cover Xarelto if it appears on the plan’s formulary. There are currently no generic alternatives available for Xarelto, ...

Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is uncertain. In this double-blind, ...